Eisai (OTCMKTS:ESALY – Get Rating) updated its FY 2023 earnings guidance on Friday. The company provided EPS guidance of $1.37-$1.37 for the period. The company issued revenue guidance of $6.03 billion-$6.03 billion.
OTCMKTS:ESALY opened at $39.79 on Friday. The company has a current ratio of 1.92, a quick ratio of 1.62 and a debt-to-equity ratio of 0.07. The company’s fifty day moving average price is $44.47 and its 200-day moving average price is $51.26. Eisai has a 1-year low of $39.66 and a 1-year high of $129.79.
Separately, Zacks Investment Research lowered Eisai from a strong-buy rating to a hold rating in a research note on Tuesday, April 12th.
Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.
Further Reading
- Get a free copy of the StockNews.com research report on Eisai (ESALY)
- Alibaba Group: Rallying on Fundamentals & Improved Macro Backdrop
- Investing in Chewy Will Require More Than One Earnings Report
- JFrog Stock is Ready to Leap
- Hormel Foods Sends A Message To The Market
- PVH Corp. Looks Sharp For A Major Reversal
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.
